Danish Novo Nordisk has announced that they due to restructuring will fire 400 employees in Denmark and China.
The Danish pharmaceutical company Novo Nordisk has on 18 September announced plans to restructure its Research & Development (R&D) organisation. That means approximately 400 employees from the company’s Danish and Chinese R&D departments will lose their jobs.
“In order to ensure that we have sufficient new research capabilities needed to support our long-term growth ambitions, a number of valued colleagues will lose their jobs,” says Mads Krogsgaard Thomsen, chief science officer, Novo Nordisk.
With the restructuring, Novo Nordisk will enable increased investment in transformational biological and technological innovation within both core and new therapy areas.
To support its strategic ambitions, the company will establish four Transformational Research Units in 2018. The biotech-like units, based in Denmark, the US and the UK, will operate as satellites of Novo Nordisk’s central R&D function and will drive innovation in priority fields such as translational cardio-metabolic research and stem cell research.
Furthermore, to drive a faster and more efficient path towards lead molecule selection and development, Novo Nordisk will significantly increase its investment in automation and digital capabilities including machine learning and artificial intelligence.
Novo Nordisk is a global healthcare company establish in 1923 and headquartered in Bagsværd, Denmark. The company employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.